semaglutide pregnancy category exposure in early and pregnancy outcomes: A case report and review of literature Semaglutide versus placebo in individuals

In 2014, the U.S

Mechanistically, research shows that GLP-1 agonists can modulate the gut microbiome composition, enhance intestinal barrier function through increased mucin production, and reduce inflammatory cytokines implicated in IBS pathogenesis

Key active compounds, including flavonoids, anthraquinones, and terpenoids, have been identified as exerting synergistic anti-gastric cancer effects

Prolonged antibiotic use may potentially lead to a vitamin K deficiency

Herbal supplements and unregulated products present additional risks

GLP-1 medications (including FDA-approved options such as semaglutide and tirzepatide) have been associated with greater average weight loss in clinical trials